+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Somatostatin Analogs Market by Molecule Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast 2025-2030- Product Image
Somatostatin Analogs Market by Molecule Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast 2025-2030- Product Image
Sale

Somatostatin Analogs Market by Molecule Type (Lanreotide, Octreotide, Pasireotide), Application (Acromegaly, Cushing's Disease, Neuroendocrine Tumors), Route Of Administration, End User, Distribution Channel, Dosage Form - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337116
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The somatostatin analogs market is experiencing significant shifts, driven by innovation in endocrine therapeutics and changing patient care expectations. Market players, healthcare providers, and stakeholders must navigate evolving clinical, regulatory, and supply chain landscapes to capture emerging opportunities in this complex domain.

Market Snapshot: Somatostatin Analogs Market

The Somatostatin Analogs Market expanded from USD 7.49 billion in 2024 to USD 8.30 billion in 2025. Projected to grow at a CAGR of 10.36%, the market is expected to reach USD 13.54 billion by 2030. This momentum is underpinned by breakthroughs in formulation technology, an increased prevalence of endocrine disorders, and broadening therapeutic use across global regions.

Scope & Segmentation

This report delivers a comprehensive analysis of industry structure, opportunities, and challenges across the somatostatin analog market. It examines critical segmentation factors, technology developments, and regional adoption patterns.

  • Molecule Type: Analysis covers Lanreotide, Octreotide, and Pasireotide, each with distinct receptor binding and clinical uses.
  • Application: In-depth insights address acromegaly, Cushing’s disease, and neuroendocrine tumors, highlighting varying patient care objectives.
  • Route Of Administration: Evaluates intramuscular and subcutaneous injection methods, balancing onset, convenience, and adherence.
  • End User: Focuses on service delivery in clinics, home care services, and hospitals, assessing shifts in patient management models.
  • Distribution Channel: Examines the roles of hospital, online, and retail pharmacies in evolving purchasing behaviors.
  • Dosage Form: Assesses cartridges and prefilled syringes, emphasizing innovations for patient-centric dosing and ease of use.
  • Regions: Covers Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key markets such as United Kingdom, Germany, France, Saudi Arabia, South Africa, and others), and Asia-Pacific (including China, India, Japan, Australia, South Korea, and more).
  • Key Companies: Detailed analysis of companies such as Novartis AG, Ipsen S.A., Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, and Accord Healthcare Ltd.

Key Takeaways for Senior Decision-Makers

  • The somatostatin analogs market is witnessing a shift toward advanced, patient-friendly formulations, including extended- and sustained-release delivery systems.
  • Broader receptor affinity in emerging molecules is unlocking new therapeutic opportunities beyond traditional indications, supporting more targeted disease management approaches.
  • Real-world evidence is increasingly influencing payer decisions, highlighting the growing importance of patient-reported outcomes in formulary placements and reimbursement strategies.
  • Global supply chain diversification is a growing priority, as market participants respond to regulatory changes, trade policy shifts, and regional demands for uninterrupted supply.
  • Regional disparities in healthcare infrastructure and reimbursement are driving differentiated commercial and access strategies, requiring localized partnerships and tailored engagement.
  • Digital health solutions, such as adherence tracking and remote patient management, are augmenting therapeutic outcomes and strengthening patient engagement in chronic endocrine disorders.

Tariff Impact: Navigating U.S. Trade Changes

New U.S. tariffs introduced in 2025 have disrupted supply chains by increasing costs of active pharmaceutical ingredient sourcing and manufacturing. Industry players are reevaluating procurement and logistics strategies, including nearshoring and dual-sourcing, to ensure continued product supply and operational resilience. Market dynamics now require agile collaborations and scenario planning among manufacturers, distributors, payers, and policy makers to balance trade compliance and patient access.

Methodology & Data Sources

This research integrates insights from primary interviews with endocrinologists, supply chain experts, and payers with secondary analysis of regulatory filings, scientific literature, and industry reports. Rigorous triangulation and expert consultations were used to refine segment assumptions and validate findings, ensuring reliability and actionable intelligence for all stakeholders.

Why This Report Matters

  • Informs executive decision-making by clarifying critical growth opportunities, supply chain challenges, and innovation drivers in the somatostatin analog landscape.
  • Empowers strategy leaders to benchmark competitive positioning and identify priorities for portfolio diversification, market entry, and operational optimization.
  • Equips stakeholders with the latest insights into policy, technology, and patient care trends for proactive planning and sustained market performance.

Conclusion

Ongoing scientific developments, regulatory shifts, and patient-centric trends continue to reshape the somatostatin analog market. Stakeholders who leverage robust evidence and collaborative models will be well-positioned to deliver value and impact in this evolving sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging long-acting somatostatin analog formulations for reduced injection frequency and improved patient adherence
5.2. Increasing clinical trial approvals for next-generation oral somatostatin analog candidates targeting NETs
5.3. Strategic collaborations between biotech firms and academic centers to develop novel non-peptide somatostatin analogs with enhanced receptor selectivity
5.4. Integration of biomarker-driven precision medicine approaches to optimize somatostatin analog therapy in neuroendocrine tumors
5.5. Expanding reimbursement coverage for high-cost somatostatin analog injectables in emerging Asia Pacific markets
5.6. Development of transdermal and implantable somatostatin analog delivery systems improving pharmacokinetic profiles
5.7. Advancements in multireceptor chimeric somatostatin-dopamine analogs showing efficacy in treatment-resistant acromegaly cases
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Somatostatin Analogs Market, by Molecule Type
8.1. Introduction
8.2. Lanreotide
8.3. Octreotide
8.4. Pasireotide
9. Somatostatin Analogs Market, by Application
9.1. Introduction
9.2. Acromegaly
9.3. Cushing's Disease
9.4. Neuroendocrine Tumors
10. Somatostatin Analogs Market, by Route Of Administration
10.1. Introduction
10.2. Intramuscular Injection
10.3. Subcutaneous Injection
11. Somatostatin Analogs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Services
11.4. Hospitals
12. Somatostatin Analogs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Somatostatin Analogs Market, by Dosage Form
13.1. Introduction
13.2. Cartridges
13.3. Prefilled Syringes
14. Americas Somatostatin Analogs Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Somatostatin Analogs Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Somatostatin Analogs Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Novartis AG
17.3.2. Ipsen S.A.
17.3.3. Teva Pharmaceutical Industries Ltd
17.3.4. Sandoz International GmbH
17.3.5. Sun Pharmaceutical Industries Ltd
17.3.6. Viatris Inc
17.3.7. Dr. Reddy's Laboratories Ltd
17.3.8. Fresenius Kabi AG
17.3.9. Hikma Pharmaceuticals PLC
17.3.10. Accord Healthcare Ltd
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. SOMATOSTATIN ANALOGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SOMATOSTATIN ANALOGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SOMATOSTATIN ANALOGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. SOMATOSTATIN ANALOGS MARKET: RESEARCHAI
FIGURE 28. SOMATOSTATIN ANALOGS MARKET: RESEARCHSTATISTICS
FIGURE 29. SOMATOSTATIN ANALOGS MARKET: RESEARCHCONTACTS
FIGURE 30. SOMATOSTATIN ANALOGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SOMATOSTATIN ANALOGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY LANREOTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY OCTREOTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PASIREOTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ACROMEGALY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CUSHING'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOME CARE SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY CARTRIDGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SOMATOSTATIN ANALOGS MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES SOMATOSTATIN ANALOGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 81. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 82. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 83. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 92. CANADA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 93. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 94. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 95. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 96. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 97. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 104. MEXICO SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 154. UNITED KINGDOM SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 155. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 156. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 157. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 158. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 159. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. GERMANY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 168. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 169. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 170. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 171. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 178. FRANCE SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 190. RUSSIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 191. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 192. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 193. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 194. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 195. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 202. ITALY SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 203. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 204. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 205. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 206. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 207. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 208. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 209. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 214. SPAIN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 238. SAUDI ARABIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 250. SOUTH AFRICA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 251. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 252. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 253. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 254. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 255. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 262. DENMARK SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 274. NETHERLANDS SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 275. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 276. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 277. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 278. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 279. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 280. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 281. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 284. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 285. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 286. QATAR SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 287. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 288. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 289. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 290. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 291. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 294. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 295. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 298. FINLAND SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 299. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 300. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 301. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 302. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 310. SWEDEN SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 311. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 312. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 313. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 314. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 322. NIGERIA SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 323. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
TABLE 324. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY MOLECULE TYPE, 2025-2030 (USD MILLION)
TABLE 325. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 326. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 327. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 328. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 329. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 331. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 332. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 333. EGYPT SOMATOSTATIN ANALOGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TA

Samples

Loading
LOADING...

Companies Mentioned

  • Novartis AG
  • Ipsen S.A.
  • Teva Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Viatris Inc
  • Dr. Reddy's Laboratories Ltd
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Accord Healthcare Ltd

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.54 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Somatostatin Analogs Market Size, Share & Trends Analysis Report by Type (Octreotide, Lanreotide, Pasireotide), Application (Acromegaly, NET), End-use (Hospitals, Clinics), and Region with Growth Forecasts, 2025-2030 - Product Image

Somatostatin Analogs Market Size, Share & Trends Analysis Report by Type (Octreotide, Lanreotide, Pasireotide), Application (Acromegaly, NET), End-use (Hospitals, Clinics), and Region with Growth Forecasts, 2025-2030

  • Report
  • 90 Pages
  • Global
From
Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Somatostatin Analogs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 82 Pages
  • Global
From
Somatostatin Analogs - Global Strategic Business Report - Product Image

Somatostatin Analogs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Somatostatin Analogs Market Report 2025 - Product Image

Somatostatin Analogs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Somatostatin Analogs Market

Somatostatin Analogs are a class of drugs used in the treatment of oncology. They are used to inhibit the release of hormones, such as growth hormone, which can be overproduced in certain types of cancer. Somatostatin Analogs are used to treat a variety of cancers, including neuroendocrine tumors, carcinoid tumors, and pancreatic islet cell tumors. They are also used to treat acromegaly, a condition caused by excessive growth hormone production. Somatostatin Analogs are administered either intravenously or subcutaneously, depending on the type of cancer being treated. The Somatostatin Analogs market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of cancer, as well as the development of new and improved drugs. The market is expected to continue to grow in the coming years, as more drugs are developed and approved for use. Some of the major companies in the Somatostatin Analogs market include Novartis, Pfizer, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.